Additional file 3 of HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
Additional file 3. Figure S2. Treatment outcome based on HER2 copy number and HER2 IHC. (A) Progression-free survival in HER2 IHC 1+/2+ and (B) HER2 IHC 3+. (C) Overall survival in HER2 IHC 1+/2+ and (D) HER2 IHC 3+ (dichotomized by the respective median HER2 copy number)
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Bild |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Seo, Jeongmin Koh, Jiwon Lee, Dae-Won Kim, Jinyong Ryu, Han Suk Lee, Kyung-Hun Kim, Tae-Yong Im, Seock-Ah |
| description | Additional file 3. Figure S2. Treatment outcome based on HER2 copy number and HER2 IHC. (A) Progression-free survival in HER2 IHC 1+/2+ and (B) HER2 IHC 3+. (C) Overall survival in HER2 IHC 1+/2+ and (D) HER2 IHC 3+ (dichotomized by the respective median HER2 copy number) |
| doi_str_mv | 10.6084/m9.figshare.26654245 |
| format | Image |
| fullrecord | <record><control><sourceid>datacite_PQ8</sourceid><recordid>TN_cdi_datacite_primary_10_6084_m9_figshare_26654245</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_6084_m9_figshare_26654245</sourcerecordid><originalsourceid>FETCH-datacite_primary_10_6084_m9_figshare_266542453</originalsourceid><addsrcrecordid>eNqdUEtOwzAQzYYFAm7AYg7QhrRNI7pEVVHYIvbWxJ40Izkf2eNAelUugwOEA7AavXkfPb0kud9kaZE95g_tIa357Bt0lG6LYp9v8_118vlkDAv3HVqo2RLsoK-hPL1uAdvBcs0aZxosjWShmoA78CwBmqlybPjyQw-ODGvx4IMbeYxpfRDdtzTr0YzYaTLfueuhj34eCSpH6AX0zDmQiCRq3lkaGMhJuIQWq1UkomoB2BkwvSbBj1jH0RmdseT9X-uX8hjfPljxt8lVjdbT3e-9SfLn09uxXBsU1CykBsctukltMjVvpNqDWjZSy0a7f9q-AFjOf38</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>image</recordtype></control><display><type>image</type><title>Additional file 3 of HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results</title><source>DataCite</source><creator>Seo, Jeongmin ; Koh, Jiwon ; Lee, Dae-Won ; Kim, Jinyong ; Ryu, Han Suk ; Lee, Kyung-Hun ; Kim, Tae-Yong ; Im, Seock-Ah</creator><creatorcontrib>Seo, Jeongmin ; Koh, Jiwon ; Lee, Dae-Won ; Kim, Jinyong ; Ryu, Han Suk ; Lee, Kyung-Hun ; Kim, Tae-Yong ; Im, Seock-Ah</creatorcontrib><description>Additional file 3. Figure S2. Treatment outcome based on HER2 copy number and HER2 IHC. (A) Progression-free survival in HER2 IHC 1+/2+ and (B) HER2 IHC 3+. (C) Overall survival in HER2 IHC 1+/2+ and (D) HER2 IHC 3+ (dichotomized by the respective median HER2 copy number)</description><identifier>DOI: 10.6084/m9.figshare.26654245</identifier><language>eng</language><publisher>figshare</publisher><subject>Cancer ; Cell Biology ; FOS: Biological sciences ; Genetics ; Medicine ; Molecular Biology ; Plant Biology ; Science Policy</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>781,1895</link.rule.ids><linktorsrc>$$Uhttps://commons.datacite.org/doi.org/10.6084/m9.figshare.26654245$$EView_record_in_DataCite.org$$FView_record_in_$$GDataCite.org$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Seo, Jeongmin</creatorcontrib><creatorcontrib>Koh, Jiwon</creatorcontrib><creatorcontrib>Lee, Dae-Won</creatorcontrib><creatorcontrib>Kim, Jinyong</creatorcontrib><creatorcontrib>Ryu, Han Suk</creatorcontrib><creatorcontrib>Lee, Kyung-Hun</creatorcontrib><creatorcontrib>Kim, Tae-Yong</creatorcontrib><creatorcontrib>Im, Seock-Ah</creatorcontrib><title>Additional file 3 of HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results</title><description>Additional file 3. Figure S2. Treatment outcome based on HER2 copy number and HER2 IHC. (A) Progression-free survival in HER2 IHC 1+/2+ and (B) HER2 IHC 3+. (C) Overall survival in HER2 IHC 1+/2+ and (D) HER2 IHC 3+ (dichotomized by the respective median HER2 copy number)</description><subject>Cancer</subject><subject>Cell Biology</subject><subject>FOS: Biological sciences</subject><subject>Genetics</subject><subject>Medicine</subject><subject>Molecular Biology</subject><subject>Plant Biology</subject><subject>Science Policy</subject><fulltext>true</fulltext><rsrctype>image</rsrctype><creationdate>2024</creationdate><recordtype>image</recordtype><sourceid>PQ8</sourceid><recordid>eNqdUEtOwzAQzYYFAm7AYg7QhrRNI7pEVVHYIvbWxJ40Izkf2eNAelUugwOEA7AavXkfPb0kud9kaZE95g_tIa357Bt0lG6LYp9v8_118vlkDAv3HVqo2RLsoK-hPL1uAdvBcs0aZxosjWShmoA78CwBmqlybPjyQw-ODGvx4IMbeYxpfRDdtzTr0YzYaTLfueuhj34eCSpH6AX0zDmQiCRq3lkaGMhJuIQWq1UkomoB2BkwvSbBj1jH0RmdseT9X-uX8hjfPljxt8lVjdbT3e-9SfLn09uxXBsU1CykBsctukltMjVvpNqDWjZSy0a7f9q-AFjOf38</recordid><startdate>20240814</startdate><enddate>20240814</enddate><creator>Seo, Jeongmin</creator><creator>Koh, Jiwon</creator><creator>Lee, Dae-Won</creator><creator>Kim, Jinyong</creator><creator>Ryu, Han Suk</creator><creator>Lee, Kyung-Hun</creator><creator>Kim, Tae-Yong</creator><creator>Im, Seock-Ah</creator><general>figshare</general><scope>DYCCY</scope><scope>PQ8</scope></search><sort><creationdate>20240814</creationdate><title>Additional file 3 of HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results</title><author>Seo, Jeongmin ; Koh, Jiwon ; Lee, Dae-Won ; Kim, Jinyong ; Ryu, Han Suk ; Lee, Kyung-Hun ; Kim, Tae-Yong ; Im, Seock-Ah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-datacite_primary_10_6084_m9_figshare_266542453</frbrgroupid><rsrctype>images</rsrctype><prefilter>images</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cancer</topic><topic>Cell Biology</topic><topic>FOS: Biological sciences</topic><topic>Genetics</topic><topic>Medicine</topic><topic>Molecular Biology</topic><topic>Plant Biology</topic><topic>Science Policy</topic><toplevel>online_resources</toplevel><creatorcontrib>Seo, Jeongmin</creatorcontrib><creatorcontrib>Koh, Jiwon</creatorcontrib><creatorcontrib>Lee, Dae-Won</creatorcontrib><creatorcontrib>Kim, Jinyong</creatorcontrib><creatorcontrib>Ryu, Han Suk</creatorcontrib><creatorcontrib>Lee, Kyung-Hun</creatorcontrib><creatorcontrib>Kim, Tae-Yong</creatorcontrib><creatorcontrib>Im, Seock-Ah</creatorcontrib><collection>DataCite (Open Access)</collection><collection>DataCite</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Seo, Jeongmin</au><au>Koh, Jiwon</au><au>Lee, Dae-Won</au><au>Kim, Jinyong</au><au>Ryu, Han Suk</au><au>Lee, Kyung-Hun</au><au>Kim, Tae-Yong</au><au>Im, Seock-Ah</au><format>book</format><genre>unknown</genre><ristype>GEN</ristype><title>Additional file 3 of HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results</title><date>2024-08-14</date><risdate>2024</risdate><abstract>Additional file 3. Figure S2. Treatment outcome based on HER2 copy number and HER2 IHC. (A) Progression-free survival in HER2 IHC 1+/2+ and (B) HER2 IHC 3+. (C) Overall survival in HER2 IHC 1+/2+ and (D) HER2 IHC 3+ (dichotomized by the respective median HER2 copy number)</abstract><pub>figshare</pub><doi>10.6084/m9.figshare.26654245</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | DOI: 10.6084/m9.figshare.26654245 |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_datacite_primary_10_6084_m9_figshare_26654245 |
| source | DataCite |
| subjects | Cancer Cell Biology FOS: Biological sciences Genetics Medicine Molecular Biology Plant Biology Science Policy |
| title | Additional file 3 of HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T05%3A43%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-datacite_PQ8&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.au=Seo,%20Jeongmin&rft.date=2024-08-14&rft_id=info:doi/10.6084/m9.figshare.26654245&rft_dat=%3Cdatacite_PQ8%3E10_6084_m9_figshare_26654245%3C/datacite_PQ8%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |